MorphoSys AG is preparing for the launch, pending US regulatory approval, of its first antibody therapeutic for cancer, marking its transition from a drug discovery company into a fully-integrated pharma enterprise. The product, tafasitamab, is being reviewed by the Food and Drug Administration with a decision expected in mid-August. It has been developed for diffuse large B cell lymphoma (DLBCL), an aggressive type of non-Hodgkin lymphoma.
